Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRWD NASDAQ:OLMA NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRWDIronwood Pharmaceuticals$3.65+0.6%$3.82$0.61▼$5.78$595.16M0.252.12 million shs1.87 million shsOLMAOlema Pharmaceuticals$9.87+1.2%$13.96$3.89▼$36.26$862.12M1.981.36 million shs1.60 million shsTVTXTravere Therapeutics$52.04+6.4%$41.70$13.88▼$52.72$4.84B1.131.86 million shs2.39 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRWDIronwood Pharmaceuticals0.00%+10.27%-0.54%+8.31%+405.75%OLMAOlema Pharmaceuticals0.00%-4.27%-28.58%-32.90%+141.91%TVTXTravere Therapeutics0.00%+13.60%+18.00%+87.19%+258.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRWDIronwood Pharmaceuticals$3.65+0.6%$3.82$0.61▼$5.78$595.16M0.252.12 million shs1.87 million shsOLMAOlema Pharmaceuticals$9.87+1.2%$13.96$3.89▼$36.26$862.12M1.981.36 million shs1.60 million shsTVTXTravere Therapeutics$52.04+6.4%$41.70$13.88▼$52.72$4.84B1.131.86 million shs2.39 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRWDIronwood Pharmaceuticals0.00%+10.27%-0.54%+8.31%+405.75%OLMAOlema Pharmaceuticals0.00%-4.27%-28.58%-32.90%+141.91%TVTXTravere Therapeutics0.00%+13.60%+18.00%+87.19%+258.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRWDIronwood Pharmaceuticals 2.43Hold$6.2370.78% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10346.81% UpsideTVTXTravere Therapeutics 2.69Moderate Buy$50.17-3.60% DownsideCurrent Analyst Ratings BreakdownLatest TVTX, OLMA, and IRWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026TVTXTravere Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$50.00 ➝ $65.006/3/2026TVTXTravere Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$59.00 ➝ $62.006/3/2026TVTXTravere Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.006/2/2026TVTXTravere Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$57.00 ➝ $67.005/22/2026OLMAOlema Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026TVTXTravere Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026OLMAOlema Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $35.005/6/2026TVTXTravere Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/6/2026TVTXTravere Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$40.00 ➝ $50.005/5/2026TVTXTravere Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $55.005/5/2026TVTXTravere Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $59.00(Data available from 6/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRWDIronwood Pharmaceuticals$296.15M2.01$0.26 per share14.18($1.61) per share-2.27OLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/ATVTXTravere Therapeutics$490.73M9.86$0.36 per share143.70$1.28 per share40.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRWDIronwood Pharmaceuticals$24.02M$0.606.08N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)TVTXTravere Therapeutics-$25.55M-$0.23N/A39.13N/A-4.00%-26.16%-3.71%8/5/2026 (Estimated)Latest TVTX, OLMA, and IRWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million5/4/2026Q1 2026TVTXTravere Therapeutics-$0.2420$0.05+$0.2920-$0.40$136.23 million$127.20 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRWDIronwood PharmaceuticalsN/A1.411.41OLMAOlema Pharmaceuticals0.0110.8810.88TVTXTravere Therapeutics3.163.133.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRWDIronwood PharmaceuticalsN/AOLMAOlema Pharmaceuticals91.78%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipIRWDIronwood Pharmaceuticals9.30%OLMAOlema Pharmaceuticals12.56%TVTXTravere Therapeutics4.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableTVTXTravere Therapeutics46092.99 million88.86 millionOptionableTVTX, OLMA, and IRWD HeadlinesRecent News About These CompaniesFrazier Life Sciences Management L.P. Decreases Stake in Travere Therapeutics, Inc. $TVTXJune 14 at 6:14 AM | marketbeat.comIs Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?June 13 at 6:10 PM | insidermonkey.comEVEREST MED (01952.HK) Signs Exclusive License and Collaboration Agreement with Travere Therapeutics, Inc. (TVTX.US), to Receive USD112.5M Upfront PaymentJune 12 at 10:16 PM | aastocks.comATravere Therapeutics (TVTX) Gets a Buy from Wells FargoJune 12 at 10:16 PM | theglobeandmail.comTravere Therapeutics (NASDAQ:TVTX) Trading 7.6% Higher on Analyst UpgradeJune 12 at 3:15 PM | marketbeat.comWells Fargo & Company Raises Travere Therapeutics (NASDAQ:TVTX) Price Target to $65.00June 12 at 10:01 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Sets New 52-Week High - Time to Buy?June 9, 2026 | marketbeat.comFiera Capital Corp Takes $33.40 Million Position in Travere Therapeutics, Inc. $TVTXJune 9, 2026 | marketbeat.comTravere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines - SlideshowJune 8, 2026 | seekingalpha.com3 Stocks That May Be Priced Below Their Estimated Value In June 2026June 8, 2026 | finance.yahoo.comTravere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Rating of "Moderate Buy" from AnalystsJune 8, 2026 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 8, 2026 | marketbeat.comBank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)June 6, 2026 | theglobeandmail.comGuggenheim Sticks to Their Buy Rating for Travere Therapeutics (TVTX)June 6, 2026 | theglobeandmail.comBNP Paribas Financial Markets Has $25.44 Million Stock Position in Travere Therapeutics, Inc. $TVTXJune 5, 2026 | marketbeat.comTravere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 CongressJune 4, 2026 | businesswire.comEverest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases ...June 4, 2026 | theglobeandmail.comTravere Therapeutics (NASDAQ:TVTX) Given Outperform Rating at WedbushJune 4, 2026 | americanbankingnews.comEverest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value ConversionJune 4, 2026 | gurufocus.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Up 5.5% - Time to Buy?June 3, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVTX, OLMA, and IRWD Company DescriptionsIronwood Pharmaceuticals NASDAQ:IRWD$3.65 +0.02 (+0.55%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.65 0.00 (-0.03%) As of 06/12/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$9.87 +0.12 (+1.23%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$9.71 -0.16 (-1.61%) As of 06/12/2026 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Travere Therapeutics NASDAQ:TVTX$52.04 +3.13 (+6.40%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$52.03 -0.01 (-0.02%) As of 06/12/2026 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
